Pfizer updates 9% Allogene ownership stake

Pfizer Inc. reports beneficial ownership of 22,032,040 shares of Allogene Therapeutics, Inc. common stock, representing 9.0% of the class.

Rhea-AI Filing Summary

Pfizer Inc. reports beneficial ownership of 22,032,040 shares of Allogene Therapeutics, Inc. common stock, representing 9.0% of the class. This percentage is based on 224,730,144 shares outstanding as of November 4, 2025, as reported in Allogene’s Form 10-Q. The lower ownership percentage in this amendment results solely from Allogene issuing more shares, not from Pfizer selling or buying stock. Pfizer and its listed executives report no transactions in Allogene shares during the prior 60 days.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Allogene (ALLO) shares does Pfizer currently beneficially own?

Pfizer beneficially owns 22,032,040 shares of Allogene common stock. This figure reflects sole voting and dispositive power over those shares, with no shared voting or dispositive authority reported in the latest ownership amendment.

What percentage of Allogene (ALLO) does Pfizer’s stake represent now?

Pfizer’s stake represents 9.0% of Allogene’s outstanding common stock. This percentage is calculated using 224,730,144 shares outstanding as of November 4, 2025, as disclosed on Allogene’s Form 10-Q cover page filed with the SEC.

Why did Pfizer’s reported percentage ownership in Allogene (ALLO) change?

The reported percentage fell because Allogene’s total shares outstanding increased. Pfizer states the decrease in its ownership percentage results solely from the higher share count reported in Allogene’s November 6, 2025 Form 10-Q, not from any Pfizer share sales.

Did Pfizer trade Allogene (ALLO) shares in the last 60 days?

Pfizer reports no transactions in Allogene common stock during the past 60 days. The amendment clarifies that, aside from the holdings previously reported, neither Pfizer nor the individuals listed on Schedule I have traded Allogene shares in that period.

Does Pfizer have sole or shared voting power over its Allogene (ALLO) shares?

Pfizer reports sole voting and sole dispositive power over 22,032,040 Allogene shares, with zero shared voting or shared dispositive power. This means Pfizer alone controls how these shares are voted and whether they are sold or otherwise disposed.

What triggered Pfizer’s latest ownership amendment for Allogene (ALLO)?

The amendment updates Pfizer’s beneficial ownership details following Allogene’s new share count in its Form 10-Q. It revises the percentage owned, clarifies that the change is due to increased outstanding shares, and restates that there were no recent Pfizer share transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 05:09 PM EST Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)

Allogene Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share (the "Common Stock")

(Title of Class of Securities)

019770106

(CUSIP Number)

Margaret M. Madden, Esq
66 Hudson Boulevard East,
New York, NY, 10001
212-733-2323

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

11/06/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 019770106

1

Name of reporting person

Pfizer Inc.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 22,032,040.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 22,032,040.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

22,032,040.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.0 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

Percent of class represented by amount in row (11) is calculated based upon 224,730,144 shares of common stock, $0.001 par value per share, outstanding as of November 4, 2025, as reported by the Issuer on the cover of its Form 10-Q for the quarterly period ended September 30, 2025 and filed with the U.S. Securities and Exchange Commission on November 6, 2025 (the "Form 10-Q"). The decrease in the percentage of shares of Common Stock held by the Reporting Person reported on this Amendment No. 4 resulted solely from the increase in the number of shares of Common Stock reported as outstanding by the Issuer in the Form 10-Q.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.001 per share (the "Common Stock")
(b)	Name of Issuer: Allogene Therapeutics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 210 East Grand Avenue, South San Francisco, CALIFORNIA , 94080.
Item 1 Comment: Explanatory Note This Amendment No. 4 (this "Amendment No. 4") to the statement on Schedule 13D originally filed with the U.S. Securities and Exchange Commission (the "Commission") on October 22, 2018, as amended by Amendment No. 1 filed on September 17, 2021, Amendment No. 2 filed on April 7, 2022 and Amendment No. 3 filed on October 25, 2023 (the "Schedule 13D"), relates to the common stock, par value $0.001 per share (the "Common Stock"), of Allogene Therapeutics, Inc., a Delaware corporation (the "Issuer"). The Issuer's principal executive offices are located at 210 East Grand Avenue, South San Francisco, California 94080. The Issuer's shares of Common Stock are listed on The Nasdaq Stock Market LLC under the ticker symbol "ALLO". Except as specifically provided herein, this Amendment No. 4 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used but not otherwise defined in this Amendment No. 4 shall have the meanings ascribed to them in the Schedule 13D. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.
Item 2.	Identity and Background
(a)	No amendment to this Item is being made.
(b)	The principal business address of Pfizer is 66 Hudson Boulevard East, New York, New York 10001-2192
(c)	No amendment to this Item is being made.
(d)	No amendment to this Item is being made.
(e)	No amendment to this Item is being made.
(f)	No amendment to this Item is being made.
Item 3.	Source and Amount of Funds or Other Consideration
	No amendment to this Item is being made.
Item 4.	Purpose of Transaction
	No amendment to this Item is being made.
Item 5.	Interest in Securities of the Issuer
(a)	The paragraphs captioned (a) - (b) of Item 5 of the Schedule 13D are hereby superseded by the following paragraphs: (a)--(b) The information related to the beneficial ownership of Common Stock by the Reporting Person set forth in Rows 7 through 13 of the cover page hereto is incorporated by reference. The decrease in the percentage of shares of Common Stock held by the Reporting Person reported on this Amendment No. 4 resulted solely from the increase in the number of shares of Common Stock reported as outstanding by the Issuer in the Form 10-Q for the quarterly period ended September 30, 2025 as filed with the U.S. Securities and Exchange Commission on November 6, 2025.
(b)	See (a).
(c)	The paragraph captioned (c) in the Schedule 13D is hereby supersed by the following paragraph: (c) Except as reported in the Schedule 13D, neither the Reporting Person nor any of the Individuals listed on Schedule I has effected any transactions in the Common Stock during the past sixty (60) days.
(d)	No amendment to this Item is being made.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	No amendment to this Item is being made.
Item 7.	Material to be Filed as Exhibits.
	Schedule I: Name, business address, present principal occupation or employment and place of citizenship of the directors and executive officers of Pfizer Inc.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Pfizer Inc.

Signature:	/s/ Madelyn D. Purcell
Name/Title:	Madelyn D. Purcell/Assistant Secretary
Date:	02/13/2026